For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
11
views
21
references
 Top references
cited by
61
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      2,489
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia : A 12-Month Phase 3 Study

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Oral sodium zirconium cyclosilicate (formerly ZS-9) binds and removes potassium via the gastrointestinal tract. Sodium zirconium cyclosilicate-associated restoration and maintenance of normokalemia and adverse events were evaluated in a two-part, open label, phase 3 trial.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found

          Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.

          Matthew Weir, George L. Bakris, David A Bushinsky … (2015)
          Hyperkalemia increases the risk of death and limits the use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) in high-risk patients. We assessed the safety and efficacy of patiromer, a nonabsorbed potassium binder, in a multicenter, prospective trial.
          Article 0 comments Cited 198 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The frequency of hyperkalemia and its significance in chronic kidney disease.

            Jeffrey C. Fink, Jacquelyn Weir, Van Hsu … (2009)
            Hyperkalemia is a potential threat to patient safety in chronic kidney disease (CKD). This study determined the incidence of hyperkalemia in CKD and whether it is associated with excess mortality. This retrospective analysis of a national cohort comprised 2 103 422 records from 245 808 veterans with at least 1 hospitalization and at least 1 inpatient or outpatient serum potassium record during the fiscal year 2005. Chronic kidney disease and treatment with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers (blockers of the renin-angiotensin-aldosterone system [RAAS]) were the key predictors of hyperkalemia. Death within 1 day of a hyperkalemic event was the principal outcome. Of the 66 259 hyperkalemic events (3.2% of records), more occurred as inpatient events (n = 34 937 [52.7%]) than as outpatient events (n = 31 322 [47.3%]). The adjusted rate of hyperkalemia was higher in patients with CKD than in those without CKD among individuals treated with RAAS blockers (7.67 vs 2.30 per 100 patient-months; P or=5.5 and or=6.0 mEq/L) hyperkalemic event was highest with no CKD (OR, 10.32 and 31.64, respectively) vs stage 3 (OR, 5.35 and 19.52, respectively), stage 4 (OR, 5.73 and 11.56, respectively), or stage 5 (OR, 2.31 and 8.02, respectively) CKD, with all P < .001 vs normokalemia and no CKD. The risk of hyperkalemia is increased with CKD, and its occurrence increases the odds of mortality within 1 day of the event. These findings underscore the importance of this metabolic disturbance as a threat to patient safety in CKD.
            Article 0 comments Cited 176 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Sodium zirconium cyclosilicate in hyperkalemia.

              David K Packham, Henrik S Rasmussen, Philip Lavin … (2015)
              Hyperkalemia (serum potassium level, >5.0 mmol per liter) is associated with increased mortality among patients with heart failure, chronic kidney disease, or diabetes. We investigated whether sodium zirconium cyclosilicate (ZS-9), a novel selective cation exchanger, could lower serum potassium levels in patients with hyperkalemia.
              Article 0 comments Cited 155 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Title: Clinical Journal of the American Society of Nephrology
                Abbreviated Title: CJASN
                Publisher: American Society of Nephrology (ASN)
                ISSN (Print): 1555-9041
                ISSN (Electronic): 1555-905X
                Publication date Created: June 07 2019
                Publication date Created: June 07 2019
                Publication date (Print): June 07 2019
                Publication date (Electronic): May 20 2019
                Volume: 14
                Issue: 6
                Pages: 798-809
                Article
                DOI: 10.2215/CJN.12651018
                PMC ID: 6556727
                PubMed ID: 31110051
                SO-VID: 321cf744-87c8-455f-9b50-5ff50ad5b2ab
                Copyright © © 2019
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content2,489

                See all similar

                Cited by61

                See all cited by

                Most referenced authors206

                See all reference authors